Abstract-One of the significant oncogen proteins is Tropomyosin Related Kinase B (Trk B) which its ligand is Brain Derived Neurotrophic Factor (BDNF). Over-expression of Trk B was observed in thyroid, ovarian and prostate cancer and multiple myeloma. BDNF bind to Trk B receptor which leads to activation of angiogenesis and proliferation pathway in tumor cell line. The aim of this study was to design novel peptides as inhibitors of Trk B receptor. Firstly, peptide library was generated; bioinformatics software for opting peptides with lowest energy, then the designed peptides were treated on OV-CAR-3 Cell line. MTT Assay was carried out to investigate the cytotoxicity and apoptosis in OV-CAR-3 Cell line resulting from designed peptides. Our findings indicated that peptide II with 350 nM is more effective OV-CAR-3 than other designed peptides, it could inhibit signaling pathway.
I. INTRODUCTION
ANCER is the second cause of death in the world wild and Millions of people are suffering from cancer [1] . There are many ways for cancer treatment including surgery, radiation therapy, chemotherapy, targeted therapies like monoclonal antibody and therapeutic peptides [2] . The peptide has many advantages than others including smaller size, high structural compatibility with target proteins and fewer drug-drug interaction complications [3] , [4] . Many proteins including RAS, WNT, MYC, ERK and TRK; So TRK have been identified as a drug target in cancer; Trk B receptor acts as an oncogen agent and its binding to BDNF ligand activates the signaling angiogenesis of tumor proliferation [5] . After binding BDNF to cyctoplasmi Trk B receptor cause autophosphorization Y484 ,Y785 actives some signaling including phosphatidyl inositol 3-kinase (PI3K) active survival and growth , MAPK/ERK and RAS/MAPK differentiation and growth also AKT cause decreasing of pro apoptotic proteins [6] , [7] . Trk B inhibition is potential target for treatment of some cancers [5, 8] because over expression and mutation in Trk B are determined in ovarian, bladder, neuroblastoma, prostate, multiple myeloma [9] , [10] . In this study we set up a computational method for designing novel stable peptides for inhibition of Trk B as cell membrane receptor of BDNF.
II. MATERIAL AND METHODS
We designed a pepetide to disrupt its binding to BDNF and blocking the activation pathways of angiogenesis .At the first step, a peptide library generated. Then generated peptides sorted based on energy score in R package. Three dimensional Structures of the selective peptides with the lowest energy predicted by using molecular dynamic method in Hyperchem 7 software.
III. RESULTS
Storing designed peptides and 3D-structure of them are shown in figure 1 IV. DISCUSSION Our result shown that bioinformatics protocol is suitable method for designing small molecule, MTT Assay shown that designed peptides acted as a inhibitor and influenced on proliferation in OV-CAR-3 cell line, peptide II had the better effect than others. this is shown that Trk B and BDNF involved in pathogenesis of different cancers, Trk B inhibitor, AZ623 inhibits BDNF-mediated signaling and neuroblastoma cell proliferation [11] . It has been also shown that Cyclotraxin can inhibit Trk B in vivo in 200 nM [12] , CEP-751 has IC50% 100 nM [13] , K252a as an inhibitor Trk B withIC50%10-30 nµM [14] , and GNF-5837 is inhibitor in vivo with IC50% 20 nM [15] .
V. CONCLUSION
We have shown that designed peptide by bioinformatics software is as a effective method for inhibiting proliferation on OV-CAR-3 cell line.
